AI assistant
Sending…
Atea Pharmaceuticals, Inc. — Director's Dealing 2024
Dec 13, 2024
33577_dirs_2024-12-12_ccbc6cd5-80ec-4657-8d5b-90f061e21039.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2024-12-10
Reporting Person: BERGER FRANKLIN M (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-10 | Common Stock | S | 359606 | $2.8461 | Disposed | 451897 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.955. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
More from Atea Pharmaceuticals, Inc.
Proxy Solicitation & Information Statement
2026
Apr 27
Major Shareholding Notification
2026
Feb 9
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Earnings Release
2026
Jan 8
Major Shareholding Notification
2025
Dec 5